ClinicalTrials.Veeva

Menu

Phase II Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD)

Kissei logo

Kissei

Status and phase

Completed
Phase 2

Conditions

Spinocerebellar Degeneration

Treatments

Drug: KPS-0373

Study type

Interventional

Funder types

Industry

Identifiers

NCT00863538
KPS1201

Details and patient eligibility

About

To evaluate the efficacy, safety and pharmacokinetics profile of KPS-0373 in patients with SCD

Enrollment

40 estimated patients

Sex

All

Ages

20+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • SCD with mild to moderate ataxia

Exclusion criteria

  • Patients with secondary ataxia
  • Patients with clinically significant hepatic, renal, or cardiovascular dysfunction

Trial design

Primary purpose

Treatment

Allocation

N/A

Interventional model

Single Group Assignment

Masking

None (Open label)

40 participants in 1 patient group

1
Experimental group
Treatment:
Drug: KPS-0373

Trial contacts and locations

3

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems